{"organizations": [], "uuid": "163ec440b7e85586ec705aa1a841418e66311c22", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-oramed-initiates-its-90-day-pivota/brief-oramed-initiates-its-90-day-pivotal-dose-ranging-clinical-study-for-oral-insulin-idUSFWN1S00OO", "country": "US", "domain_rank": 408, "title": "BRIEF-Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study For Oral Insulin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T15:25:00.000+03:00", "replies_count": 0, "uuid": "163ec440b7e85586ec705aa1a841418e66311c22"}, "author": "", "url": "https://www.reuters.com/article/brief-oramed-initiates-its-90-day-pivota/brief-oramed-initiates-its-90-day-pivotal-dose-ranging-clinical-study-for-oral-insulin-idUSFWN1S00OO", "ord_in_thread": 0, "title": "BRIEF-Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study For Oral Insulin", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "clinical study for oral insulin reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "oramed pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 23, 2018 / 12:25 PM / Updated 12 minutes ago BRIEF-Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study For Oral Insulin Reuters Staff 1 Min Read \nApril 23 (Reuters) - Oramed Pharmaceuticals Inc: \n* ORAMED INITIATES ITS 90-DAY PIVOTAL DOSE-RANGING CLINICAL STUDY FOR ORAL INSULIN Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-23T15:25:00.000+03:00", "crawled": "2018-04-23T15:41:03.007+03:00", "highlightTitle": ""}